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Interim analyses are routinely used to monitor accumulating data in clinical tri-
als. When the objective of the interim analysis is to stop the trial if the trial is
deemed futile, it must ideally be conducted as early as possible. In trials where
the clinical endpoint of interest is only observed after a long follow-up, many
enrolled patients may therefore have no information on the primary endpoint
available at the time of the interim analysis. To facilitate earlier decision-making,
one may incorporate early response data that are predictive for the primary
endpoint (eg, an assessment of the primary endpoint at an earlier time) in the
interim analysis. Most attention so far has been given to the development of
interim test statistics that include such short-term endpoints, but not to deci-
sion procedures. Existing testsmoreover performpoorlywhen the information is
scarce, eg, due to rare events, when the cohort of patients with observed primary
endpoint data is small, or when the short-term endpoint is a strong but imper-
fect predictor. In view of this, we develop an interim decision procedure based
on the conditional power approach that utilizes the short-term and long-term
binary endpoints in a framework that is expected to provide reliable inferences,
even when the primary endpoint is only available for a few patients, and has the
added advantage that it allows the use of historical information. The operational
characteristics of the proposed procedure are evaluated for the phase III clinical
trial that motivated this approach, using simulation studies.
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1 INTRODUCTION
Interim analyses are routinely used in clinical trials to guide trial design modifications and early stopping. They are for
instance used to decide whether the trial should be stopped for futility,1,2 in case the state of evidence at the time of the
interim analysis leaves little hope that evidence of superiority would be found if the trial were to continue. The statistical
rule to guide the decision of whether or not to stop the trial early for futility is often based on conditional power.3-6 This
monitoring approach quantifies the probability that the null hypothesis will be rejected at th end of the study with a given
statistical test, given the primary endpoint data observed thus far. Computations of conditional power usually assume that
the future primary endpoint data will either be generated under parameter values specified in the initial study design (ie,
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under the design assumption), or that they arise from the same distribution that generated the observed data collected
so far, or that they will be generated under the null hypothesis. We will focus on the conditional power under the design
assumption but our proposal will also apply for these alternative assumptions.
In trials where the clinical endpoint of interest is only observed after a long period of treatment-free follow-up, many
enrolled patients may have no information on the primary endpoint available at the time of the interim analysis. Restrict-
ing the interim analysis to those patients with long-term information available may then result in lack of information to
support futility decisions. Delaying the time of the interim analysis to a time where a sufficient number of patients have
their primary endpoint available may be less ethical and increase the costs if the trial was deemed futile. In particular, it
may rule out the possibility of stopping recruitment as all patientsmay then have been enrolled already. To support futility
decisions, it then seems of interest to replace the long-term primary endpoint by a short-term surrogate, when available.
This, however, is only justified under the strong assumption that tests for short-term and long-term treatment differences
are equivalent.7
For instance, the motivating phase III clinical trial was designed to evaluate the efficacy of a new experimental treat-
ment for multidrug-resistant tuberculosis on top of the standard of care regimen (referred to as background regimen BR)
as compared to placebo plus BRwith regard to the proportion of subjects with a favorable treatment outcome (ClinicalTri-
als.gov, NCT00449644).8 This requires confirmed culture conversion 60 weeks after randomization. Besides the clinical
endpoint of interest, confirmed culture conversion (cure) was planned to be assessed 16 weeks after randomization (see
Supplementary Material for an overview of the study design). An interim analysis to decide if the trial should be stopped
for futility would ideally employ the 16-week endpoint for patients for whom this, but not the 60 week endpoint is avail-
able. Basing the interim analysis only on the short-term endpoint is generally not satisfactory as it shifts the focus away
from the primary long-term endpoint. Treatments may indeed be very similar with respect to their short-term effect, but
differ with respect to their long-term effect, or vice versa. This may, for example, be the case when treatments differ in
time to response. Several approaches in the literature therefore, instead, use information on short-term endpoints only
to predict the primary long-term endpoint when it is missing. Marschner and Becker9 introduced a Wald test based on
the probability difference parameterization to address this problem for binary outcomes assessed at two time points dur-
ing follow-up. Kunz et al10 applied this estimator to a two-stage phase II oncology trial. Niewczas et al11 constructed
decision-making rules based on the conditional power of the resulting test statistic assuming a Brownian motion struc-
ture. Wüst and Kieser12 discussed incorporation of binary long- and short-term data in blinded sample size reassessment
methods. Sooriyarachchi et al13 presented a score test, based on the log-odds ratio for success at the final time point, for
incorporating patients with binary assessments taken at three fixed time points, with the third assessment time being the
primary one. Whitehead et al14 compared the performances of four methods for incorporating binary observations taken
at two time points into interim analyses: the score and Wald approaches, each with the log-odds ratio and probability
difference parameterizations. Their simulations have shown that all four approaches have good properties regarding the
power and type I error in moderate to large sample sizes. Similar methods for continuous data have also been consid-
ered in the literatures.15-20 For example, Galbraith and Marschner15 adapted and extended the methodology described in
the work of Marschner and Becker9 to include continuous endpoints assessed at an arbitrary number of follow-up times.
Hampson and Jennison17 generalized this to a group sequential design for the situation where the primary endpoint is
measured with delay.
In this article, we aim to improve performance in settings where the asymptotic theory, as used for the single known
decision procedure for this problem,11 may fail. In particular, when the number of patients with complete data at the
interim assessment is small, or the considered event is rare, the variance estimator ofMarschner and Becker9 may perform
poorly. A decision procedure based on this test statistic may thenmisrepresent the amount of information that is available
at the interim assessment. Similar problems may occur when the short-term endpoint is a strong predictor of the primary
endpoint, for then their degree of dependence may be difficult to assess well. We will overcome this problem by making
use of a Bayesian procedure, which avoids asymptotic approximations, thereby giving rise to a decision procedure that
is more widely applicable. This not only provides a more robust conditional power21 but also brings the possibility of
including historical data,which are often available fromearlier phases in development. If, for example, accrual occurs very
quickly, the availability of primary endpoint data will be limited until close to the end of the study. This makes it difficult
to estimate the long-term response probability with a certain degree of precision early in the study. Using historical data to
inform Bayesian priors may then help improve the certainty of decisions made during drug development and as a result,
reduce overall costs. The need to incorporate historical datawasmotivated by the tuberculosis example, introduced earlier
in this section, where prior phase IIb trial data were available. Like Marschner and Becker,9 our focus throughout will be
on binary short-term and long-term endpoints.
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1.1 Motivating context
Themethods of this paper are likely to find greatest applicability in interim analyses of long-term binary endpoints where
the treatment under study is intended to cause a favorable/unfavorable short-term response that then could be sustained
or lost in the long-term. For example, in infectious diseases clinical trials, the clinical endpoint is often designed to evaluate
some form of disease remission after a sufficiently long treatment-free follow-up period. Certain subjects may achieve
response (virus-free) on treatment and continue to respond after treatment (and cure), while some relapse only after
stopping the treatment. Others may not achieve response at all.
2 INCORPORATION OF INTERMEDIATE DATA
2.1 Setting and definitions
The methodology is introduced for the case of a two-treatment randomized controlled trial in n patients, where the pri-
mary long-term endpoint Y and the secondary short-term endpoint X on each subject are dichotomous observations.
Assume that Y is evaluated 𝜏Y time after randomization, and that X is evaluated using the same criteria at time 𝜏X ≤ 𝜏Y,
both fixed and identical time points for all subjects. Define PY𝑗 and PX𝑗 ( j ∈ {0, 1}) as the probabilities of, respectively, a
successful outcome at the end of trial (time point 𝜏Y) and a successful short-term read-out at time point 𝜏X, in the exper-
imental ( j = 1) and control ( j = 0) arm. The primary hypothesis of interest, H0 ∶ PY1 = PY0 or 𝛿 ∶= PY1 − PY0 = 0, will
be tested against the one-sided alternative, HA ∶ PY1 > PY0 or 𝛿 > 0 at level 𝛼 with power 1 − 𝛽. To evaluate this hypothe-
sis, a Z-statistic for the difference in proportions with pooled variance will be employed, although our proposal is readily
applicable to any Z-test statistic of this hypothesis. Suppose now that an interim analysis of the primary long-term end-
point Y will be conducted at information fraction tX for X and tY for Y, representing, respectively, the ratio of the number
of patients with observed short-term endpoint data at the time of the interim analysis and the planned total sample size,
and the ratio of the number of patients with observed long-term endpoint data at the time of the interim analysis and
the planned total sample size. These indicate, starting from the beginning of the study, how far through the trial we are.
Throughout, we will index an interim analysis by time t, with t fully determined by information fraction tX and/or tY. In
this paper, the main focus will be on the conditional power at a given information fraction tX and/or tY assuming the dis-
tribution of the future primary endpoint data will be generated under the design assumed parameter values PY1 = 𝜋1 and
PY0 = 𝜋0, with 𝜋1 and 𝜋0 the values that were used for powering the study.
2.2 Conceptual proposal
In the absence of early read-outs, the conditional power calculations are based on only two cohorts of patients.3,4,22 The
first cohort includes all patients for whom the primary endpoint Y has been observed. The second cohort consists of all
patients who have not yet been followed through to the long-term follow-up time 𝜏Y. Their future primary endpoint data
are then assumed to follow a Bernoulli distribution with probability determined by the design assumptions. We will refer
to this method, where one endpoint is used, as the standard method.
When early response data are available, we can distinguish three cohorts of patients (Figure 1) at information fraction t:
a first cohort of all subjectswith both endpoints observed, a second cohort of all subjectswith only the short-term endpoint
X observed, and a third cohort of all subjects without available data on X and Y. Our main motivation is to develop a
method that extends the standard method by using all the available data and reduces to it when X is independent of Y.
The future primary endpoint data for patients in cohort 3 are assumed to follow a Bernoulli distribution with probabil-
ity determined by the design assumptions in each treatment arm. Our aim is then to use short-term endpoint data X to
improve the efficiency of the interim analysis on the long-term endpoint Y. This will be done by prediction of the unob-
served primary endpoint Y based on early response data X for the subjects in cohort 2. Accordingly, the future primary
endpoint data for early responders and early nonresponders in each treatment arm of cohort 2 are assumed to follow a
Bernoulli distribution conditional on the early response data with probability P(Y = 1 |X = 1,A = j) for early respon-
ders and P(Y = 1 |X = 0,A = j) for early nonresponders in the experimental arm (A = 1) and the control arm (A = 0).
It is tempting to extract these conditional probabilities directly from the available historical and cohort 1 data. However,
this has the drawback that these probabilities then do not reduce to the design assumptions 𝜋1 and 𝜋0 when X is inde-
pendent of Y, and that the approach hence does not extend the standard method. We therefore propose to parameterize
the joint distribution of the repeated binary data in terms of PY𝑗 and the conditional probabilities P(X = 1 |Y = 1,A = j)
and P(X = 1 |Y = 0,A = j), denoted by, respectively, PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0, in treatment arm j ∈ {0, 1}. This variation
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FIGURE 1 Available data at the interim analysis. Note that “cured” and “not cured” correspond with Y = 1 and Y = 0, respectively
[Colour figure can be viewed at wileyonlinelibrary.com]
independent parameterization allows to incorporate the design assumption via PY𝑗 , and to extract PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0
from all information available in cohort 1 at the interim analysis. In doing so, we are assuming that the data observed in
cohort 1 are representative with regard to PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0 for cohort 2. Using Bayes' theorem, we finally obtain
P (Y = 1|X = 1,A = 𝑗) = PX𝑗 |Y𝑗=1PY𝑗PX𝑗 |Y𝑗=1PY𝑗 + PX𝑗 |Y𝑗=0(1 − PY𝑗 )
P (Y = 1|X = 0,A = 𝑗) = (1 − PX𝑗 |Y𝑗=1)PY𝑗(
1 − PX𝑗 |Y𝑗=1)PY𝑗 + (1 − PX𝑗 |Y𝑗=0) (1 − PY𝑗) .
We further define PdY𝑗 |X𝑗=1 and PdY𝑗 |X𝑗=0 as these conditional probabilities evaluated under the design assumptions
PdY𝑗 |X𝑗=1 =
P(1)X𝑗 |Y𝑗=1𝜋𝑗
P(1)X𝑗 |Y𝑗=1𝜋𝑗 + P(1)X𝑗 |Y𝑗=0(1 − 𝜋𝑗)
PdY𝑗 |X𝑗=0 =
(
1 − P(1)X𝑗 |Y𝑗=1
)
𝜋𝑗(
1 − P(1)X𝑗 |Y𝑗=1
)
𝜋𝑗 +
(
1 − P(1)X𝑗 |Y𝑗=0
)
(1 − 𝜋𝑗)
,
(1)
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FIGURE 2 Change in predicted P(2)Y𝑗 = P
d
Y𝑗 |X𝑗=1P(2)X𝑗 + PdY𝑗 |X𝑗=0(
1 − P(2)X𝑗
)
when P(1)Y𝑗 is smaller than the design assumption
as a function of the strength of the association
log
(
P(Y=1|X=1,A=𝑗,C=1)P(Y=0|X=0,A=𝑗,C=1)
P(Y=0|X=1,A=𝑗,C=1)P(Y=1|X=0,A=𝑗,C=1)
)
, where C = 1 for subjects
in cohort 1
where the superscripts (m) form = 1, 2, 3 express that the corresponding probability will be estimated based on the data
in cohortm. We can now verify that the proposedmethod reduces to the standardmethodwhen X and Y are independent.
Indeed, in that case, P(1)X𝑗 |Y𝑗=1 = P(1)X𝑗 |Y𝑗=0 = P(1)X𝑗 , and thus, PdY𝑗 |X𝑗=1 =
P(1)X𝑗 |Y𝑗=1𝜋𝑗
P(1)X𝑗 |Y𝑗=1𝜋𝑗+P(1)X𝑗 |Y𝑗=0(1−𝜋𝑗 )
= 𝜋𝑗 ; similarly, PdY𝑗 |X𝑗=0 = 𝜋𝑗 .
Furthermore, when X = Y in cohort 1 so that P(1)X𝑗 |Y𝑗=1 = 1 and P(1)X𝑗 |Y𝑗=0 = 0, then PdY𝑗 |X𝑗=1 =
P(1)X𝑗 |Y𝑗=1𝜋𝑗
P(1)X𝑗 |Y𝑗=1𝜋𝑗+P(1)X𝑗 |Y𝑗=0(1−𝜋𝑗 )
= 1 and
similarly, PdY𝑗 |X𝑗=0 = 0. In that case, the proposal thus acknowledges that all information on Y is obtained for patients in
cohort 2. More generally, Figure 2 shows the relation between the log odds ratio (for the association between X and Y) and
the marginal outcome probabilities P(2)Y𝑗 in cohort 2. If the observed X distributions in cohorts 1 and 2 are equal, then P
(2)
Y𝑗
varies between the observed value P(1)Y𝑗 and the design assumption (Figure 2). If the observed X distribution in cohort 2
deviates from the X distribution observed in cohort 1, P(2)Y𝑗 does not need to lie in between P
(1)
Y𝑗
and the design assumption.
2.3 Analytical proposal
In large studies where a test statistic Z with normal approximation is appropriate, we can approximate the condi-
tional power for the observed X and Y data, denoted by Dt, at any interim analysis time t. For a given value of PdY |X =
(PdY1|X1=1,PdY1|X1=0,PdY0|X0=1,PdY0|X0=0)′ and assuming that PY1 = 𝜋1 and PY0 = 𝜋0 for given values 𝜋1 and 𝜋0 (eg, design
assumptions), using analytical expressions along similar lines as in the work of Lan andWittes22 gives conditional power
CPt
(
𝜋1, 𝜋0|PdY |X) ≡ P (rejectH0 at final analysis |Dt , PdY |X , 𝜋1 , 𝜋0)
= P
(
Z1 ≥ z1−𝛼|Dt,PdY |X , 𝜋1, 𝜋0)
= 1 − Φ
(
z1−𝛼 − Ec(Z1)√
Varc(Z1)
)
,
(2)
with Z1 the test statistic at the end of the trial, z1−𝛼 the (1− 𝛼)-quantile of the standard normal distribution, 𝛼 the signifi-
cance level, and Ec(·) and Varc(·) the conditional expectation and variance of the test statistic, given the observed data at
the interim evaluation Dt, the parameter PdY |X and given values 𝜋1 and 𝜋0 for the parameters of interest. To define Ec(·)
and Varc(·), let mk,j be the number of subjects in cohort k of treatment group j (k = 1, 2, 3; j = 0, 1), z(1) the test statis-
tic in cohort 1, and n1 and n0, respectively, the planned total sample sizes in the experimental and control arm. Using
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a test statistic Z1 with normal approximation, the asymptotic mean Ec(·) and variance Varc(·) can be expressed as (see
Supplementary Material)
Ec(Z1) = z(1)
√
m1,0
n0
+
𝜋∗1
(
PdY |X
)
− 𝜋∗0
(
PdY |X
)
𝜎
√
1
r + 1
m2,0√
n0
+ 𝜋1 − 𝜋0
𝜎
√
1
r + 1
m3,0√
n0
Varc(Z1) =
𝜎2p
𝜎2
m2,0
n0
+
m3,0
n0
,
where r = n1n0 and
𝜋∗1
(
PdY |X
)
= P(2)X1 P
d
Y1|X1=1 +
(
1 − P(2)X1
)
PdY1|X1=0,
𝜋∗0
(
PdY |X
)
= P(2)X0 P
d
Y0|X0=1 +
(
1 − P(2)X0
)
PdY0|X0=0,
𝜎2p =
1(
1
r + 1
) [1r {P(2)X1 PdY1|X1=1 (1 − PdY1|X1=1) + (1 − P(2)X1)PdY1|X1=0 (1 − PdY1|X1=0)}
+
{
P(2)X0 P
d
Y0|X0=1
(
1 − PdY0|X0=1
)
+
(
1 − P(2)X0
)
PdY0|X0=0
(
1 − PdY0|X0=0
)}]
,
𝜎 =
√
p̄(1 − p̄), where p̄ = n1𝜋1 + n0𝜋0n1 + n0
.
Note that the three terms of Ec(Z1) correspond with the three different cohorts, while Varc(Z1) only includes terms for
cohorts 2 and 3. The fractions
√m𝑗,0
n0
( j = 1, 2, 3) and m𝑗,0n0 ( j = 2, 3) represent how much information in the asymptotic
expectation and variance, respectively, is explained by the different cohorts. This approximation uses r = n1n0 =
m1,1
m1,0
=
m2,1
m2,0
= m3,1m3,0 , which improves with increasing sample size. The above procedure is not readily feasible, however, because
the conditional probabilitiesPdY |X are unknown. Data from earlier studies (eg, phase IIb data in themotivating study)may
provide, albeit with uncertainty, an initial estimate. The observed data at the interim analysis allow to further improve
these estimates, but acknowledging the resulting uncertainty can be difficult, eg, when in a small cohort 1, we find X = Y
for all subjects. We will therefore approximate the joint sampling distribution of PdY |X by the joint posterior distribution,
which is ideally specified based on historical data. A detailed description of typical distributions is given in Section 2.3.1.
We can then eliminate PdY |X from the conditional power formula (2) via integration
CPt (𝜋1, 𝜋0) = ∫ P
(
rejectH0 at final analysis | Dt , PdY |X , 𝜋1 , 𝜋0) 𝑓 (PdY |X | Dt, 𝜋1, 𝜋0,H) dPdY |X
= ∫ CPt
(
𝜋1, 𝜋0 | PdY |X) 𝑓 (PdY |X | Dt, 𝜋1, 𝜋0,H) dPdY |X
= E
[
CPt
(
𝜋1, 𝜋0 | PdY |X) | Dt, 𝜋1, 𝜋0,H] ,
with 𝑓 (PdY |X |Dt, 𝜋1, 𝜋0,H) the (posterior) probability density of PdY |X given the observed data Dt at the interim analysis,
assumptions 𝜋1 and 𝜋0 about the parameters of interest and the prior information H that includes the historical data.
We refer to this quantity as the expected conditional power. The (posterior) probability distribution of PdY |X allows us to
repeatedly sample a sufficient number of vectors PdY |X = (PdY1|X1=1,PdY1|X1=0,PdY0|X0=1,PdY0|X0=0)′ from the (posterior) proba-
bility density 𝑓 (PdY |X |Dt, 𝜋1, 𝜋0,H), calculate the conditional power for each sampled vector of PdY |X values via formula (2),
and subsequently take the average over all these conditional power values. If the expected conditional power is below a
certain, predefined cutoff value, the trial will be stopped and futility recommended. Guidelines for determining this cutoff
are given in Section 2.4.
For nonnormal tests (eg, Pearson chi-square test) or when the number of patients in cohort 1 is small (ie, less than 5
expected events under the null hypothesis in one of the arms), we can determine the conditional power for a given value
of PdY |X via Monte Carlo simulations instead. As before, we then sample a sufficient number of replicates for PdY |X from its
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(posterior) probability distribution. For each value of PdY |X , we simulate the unobserved primary endpoint for each of the
patients in cohorts 2 and 3. For the patients in cohort 2, this is done by sampling the values of the primary endpoint from
a Bernoulli distribution with probability PdY𝑗 |X𝑗=1 or PdY𝑗 |X𝑗=0 ( j = 0, 1), depending on whether the subject has achieved the
early response or not. These distributions are specific for each randomized arm. For patients in cohort 3, we sample the
values of the primary endpoint from a Bernoulli distribution with probability 𝜋1 and 𝜋0 in, respectively, the experimental
and control arm. Based on the observed and simulated primary endpoint data, we then evaluate the test. The conditional
power is then defined as the fraction of trials in which the primary hypothesis is rejected at the prespecified significance
level. When there are less than 5 expected events under the null hypothesis in one of the arms, then this is best based on
Fisher's exact test or the test statistic after adding pseudo data, 1 success and 1 failure, to each sample group.23
2.3.1 Posterior distribution of PdY |X
Assuming prior independence between (PdY1|X1=1,PdY1|X1=0) and (PdY0|X0=1,PdY0|X0=0), we can write 𝑓 (PdY |X |Dt, 𝜋1, 𝜋0,H) as the
product of the posteriors 𝑓 (PdY1|X1=1,PdY1|X1=0|Dt, 𝜋1, 𝜋0,H) and 𝑓 (PdY0|X0=1,PdY0|X0=0|Dt, 𝜋1, 𝜋0,H). Since PdY𝑗 |X𝑗=1 and PdY𝑗 |X𝑗=0
are determined by PY𝑗 , PX𝑗 |Y𝑗=1, and PX𝑗 |Y𝑗=0, a joint distribution for PdY𝑗 |X𝑗=1 and PdY𝑗 |X𝑗=0 is implied by a joint distribution
for the latter two parameters and the assumed values 𝜋1 and 𝜋0 for PY𝑗 in arm j. Assuming a priori independence between
these three parameters, we can choose the prior distributions for the latter two separately.
We recommend noninformative Beta(0.5, 0.5) priors on PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0 corresponding with a 2x2 table
cross-classified according to X and Y with value 0.5 in each cell. When historical data are representative for the current
trial with respect to the conditional probabilities PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0, we can use these data to update these noninforma-
tive prior distributions as follows. The informative Beta prior distribution for PX𝑗 |Y𝑗=1 has parameters 0.5+x and 0.5+m−x
if x out of the m patients with Y = 1 in treatment arm j of the historical dataset are early responders. Likewise, we can
update the noninformative Beta(0.5, 0.5) prior distributions for PX𝑗 |Y𝑗=0 to informative priors with parameters 0.5+ y and
0.5+ s− y if y out of the s patients with Y = 0 in treatment arm j of the historical dataset are early responders. In practice,
one needs to decide how much weight to give to the prior patients, given that these patients come from another study
and thus should not be given larger weights than cohort 1 patients. For more information on how to use prior belief of
clinicians and historical data to elicit prior distributions, we refer the reader to the work of Spiegelhalter et al.24 If the
historical data are not representative, noninformative priors may be more appropriate.
The likelihoods for PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0 are based on cohort 1 data and allow us to subsequently update the priors as
before but now using cohort 1 data instead of the historical data. The posterior distributions allow to repeatedly sample
replicates for PX𝑗 |Y𝑗=1 and PX𝑗 |Y𝑗=0 independently. Assuming PY𝑗 = 𝜋𝑗 , we can derive values for (PdY𝑗 |X𝑗=1,PdY𝑗 |X𝑗=0) via the
analytical expressions (1) in both treatment arms.
2.4 Cutoff for the conditional power
Acutoff on the conditional power values specifies the value belowwhichwe stop the trial for futility. Its choice is important
when designing the decision rule; to avoid an increase in type II error while having sufficient “power” of a correct futility
decision.25 If the cutoff point is chosen too low (high), the trial will be stopped too rarely (frequently). It is therefore
important to select a cutoff value that limits the impact on the power of the trial to detect true superiority. The type II
error probability can be partitioned as the probability of stopping for futility (and of a type II error) at the prespecified
interim analysis plus the probability of continuation and nonsignificance at the final analysis.4
One approach for choosing an appropriate cutoff is to prespecify the minimal total power (or corresponding maximal
power loss relative to an analysis without futility stopping) one wishes for the protocol planned superiority scenario(s). In
particular, we infer a corresponding cutoff by running a sufficient number of simulations under the different scenarios.
For a given cutoff and scenario, the probability to stop for futility is calculated as the fraction of trials in which the decision
was to stop.We determine for each scenario themaximum cutoff for which the total power falls just above the prespecified
minimal total power for that scenario. The final cutoff is the minimum over all these cutoffs.
3 SIMULATION STUDY
We carried out different simulation studies to compare the performance of the proposed method to the existing methods
and to evaluate its operational characteristics under a variety of futility and superiority scenarios. The cutoff criterion, as
described in Section 2.4, is used to investigate and compare the properties of the different methods.
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3.1 Simulation settings
In themotivating phase III clinical trial, superiority of the experimental arm over the control arm is claimed if the propor-
tion of subjects with favorable treatment outcome 60 weeks after randomization is significantly higher compared to the
control arm at a one-sided significance level of 2.5%. Assuming a favorable treatment outcome rate of 60% and 73% in the
control and experimental arm, respectively, 275 patients in both arms are required to attain 90% power with a Z-statistic
for the difference in proportions with pooled variance.26
Endpoint data are generated from a repeated binary data model under different futility/superiority scenarios for the
proportion of subjects achieving a favorable outcome Y, varying assumptions on the proportion of subjects achieving X
and varying assumptions (strong, assumed, and weak) on the log odds ratio logOR𝑗 of Y for early responders versus early
nonresponders in treatment arm j ∈ {0, 1}. Particularly, the short-term endpoint data X are sampled from a Bernoulli
distribution with probability PX1 and PX0 in, respectively, the experimental and control arm. Accordingly, the future pri-
mary endpoint data for early responders and early nonresponders in each treatment arm are sampled from a Bernoulli
distribution with probabilities conditional on the early response data. These conditional probabilities are determined by
the marginal probabilities for X and Y as well as the log odds ratios. Table 1 provides an overview of the selected popula-
tion models. Three correlation scenarios (ie, “weak,” “assumed,” and “strong”) were generated, whereby the correlation
was weaker, the same, and stronger, respectively, than the correlation observed in the phase IIb data. In addition to these
correlations, a perfect predictor X of Y (SUP.1 and FUT.1) and a very strong predictor X of Y (FUT.3) are considered. We
furthermore assume that, at the interim analysis, 10% of the patients have complete observations on the long-term out-
come such that tY = 0.10 and 40% of short-term observations are available such that tX = 0.40. This corresponds with an
average of 54 patients in cohort 1, 166 in cohort 2, and 330 in cohort 3. These targeted proportions are recommended as
the minimum values to obtain a reasonable probability to stop for true futility and a negligible probability to incorrectly
stop under superiority in this example.23 They are based on projected recruitment at that time.
First, we compare the performance of the proposed method to the standard method and the method introduced by
Niewczas, Kunz, and König11 (referred to as method NKK). In addition, we investigated different strengths of association
between both endpoints and the influence of the information fraction on the cutoff value and the “power” of a correct
futility decision.
Every scenario was run 100 000 times. For each simulated trial, the conditional power was calculated based on the
analytical approximations given in Section 2.3 for 2500 posterior samples for PdY |X . Prior distributions were selected based
on the real phase IIb data. Details are given in Supplementary Material. For each scenario and decision criterion, the
probability to stop for futility was calculated as the fraction of trials in which the decision was to stop. The R-code is
available at https://github.com/kelvlanc/FutilityStopping.
3.2 Simulation results
3.2.1 Selecting a criterion for decision-making
For method comparison, a cutoff was set in such a way that a maximum reduction of 1% in power relative to an analysis
without futility decisions is allowed under the most plausible superiority scenarios SUP.2 and SUP.5 (see Table 1) and
a limited power loss (< 5%) under the less expected and even misleading scenarios (eg, SUP.3, whereby at interim, the
proportion of subjects achieving X is not different between the randomized groups). The probability to stop for futility
and the overall power in function of the cutoff points are shown in Supplementary Material. Similar patterns in opposite
directions are seen. The overall power decreases with increasing cutoff points, but stays around the design power of
0.90 up to cutoff points of around 0.51 under the different superiority scenarios, except under SUP.3. Since we also want
a reasonable probability to stop early in case of true futility and the probability to stop for futility is increasing with
increasing cutoff points, a stopping criterion of 0.51 for the expected conditional power appears to perform best in terms
of a limited power inflation (< 1% under SUP.2 and SUP.5) and a reasonable probability of stopping for true futility. The
probability to stop under a true futility scenario is 44% under FUT.1, 44.5% under FUT.3 and varies from approximately
7.5% to 9% for the scenarios (except FUT.5) under theweak log odds ratio, from approximately 24% to 34% for the scenarios
(except FUT.5) under the assumed log odds ratio and from approximately 25% to 44% for the scenarios (except FUT.5)
under the strong log odds ratio (Table 2 and Supplementary Material). The probabilities to stop under futility scenario
FUT.5, whereby at interim, a difference in proportion of subjects achieving a favorable treatment outcome X in favor
of the experimental treatment is observed, under the weak, assumed, and strong log odds ratio are 5%, 18%, and 19%,
respectively.
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TABLE 2 Probability to stop for futility under
different futility scenarios for the proposed
method, the NKK method11 and the standard
conditional power for tX = 0.40 and tY = 0.10.
The cutoff values were determined based on a
maximum 1% power reduction under SUP.2 and
SUP.5, and a limited power loss [< 5%] under the
less expected scenarios. Since FUT.1 is the
futility scenario where X = Y, and thus
logOR1 = logOR0 = ∞, the results are only
displayed for the assumed log odds ratio. Similar
for FUT.3 where we only have a (very) strong log
odds ratio
Weak log odds ratio
FUT.1 FUT.2 FUT.3 FUT.4 FUT.4b FUT.5 FUT.6
Proposal - 8.45 - 7.50 8.12 5.34 9.37
NKK - 2.26 - 2.30 2.27 2.19 2.22
Standard method - 12.32 - 12.32 12.32 12.32 12.32
Assumed log odds ratio
FUT.1 FUT.2 FUT.3 FUT.4 FUT.4b FUT.5 FUT.6
Proposal 44.08 34.24 44.50 24.15 25.63 17.93 26.07
NKK 63.46 9.91 53.53 6.17 9.85 6.89 6.30
Standard method 12.32 12.32 12.32 12.32 12.32 12.32 12.32
Strong log odds ratio
FUT.1 FUT.2 FUT.3 FUT.4 FUT.4b FUT.5 FUT.6
Proposal - 44.39 - 28.85 29.26 19.42 25.12
NKK - 28.95 - 11.09 13.73 15.05 8.47
Standard method - 12.32 - 12.32 12.32 12.32 12.32
Abbreviation: NKK, Niewczas, Kunz, and König.
3.2.2 Comparison with the standard conditional power and method NKK
In this section, we compare the expected conditional power with the standard approach and method NKK. The latter
assumes a Brownian motion structure to calculate the conditional power based on a binary outcome measured at two
time points. We refer the reader to Supplementary Material for further details.
In each trial, interim data were generated for 220 of the 550 patients (tX = 0.40) and primary endpoint data for 54 of
them (tY = 0.10). The cutoff value is determined using the same approach as for our proposal (see Section 3.2.1). Early
stopping for futility is recommended when the conditional power falls below 0.73 when the standard approach is used,
below 0.60 when method NKK is used, or below 0.51 when the expected conditional power method is used. Note that the
most appropriate cutoff value differs between themethods, since, for eachmethod, a different cutoff value leads to a small
to negligible probability of false early stopping in case of true superiority (maximum reduction of 1% in power under the
most plausible superiority scenarios and a limited power loss [< 5%] under the less expected) and a reasonable probability
of stopping for true futility. The probabilities to stop for futility under the different true futility scenarios are displayed in
Table 2. Note that the superiority as well as the futility scenarios coincide when evaluating the standard conditional power
since we are only evaluating the primary endpoint data, which are simulated under the same distributions (eg, binomial
distributions with probabilities 0.60 and 0.73 for, respectively, the control and treatment arm under superiority).
It can be seen that the overall probability to stop for futility increases when using the proposal incorporating short-term
endpoints compared to the standard approach, except at a weak log odds ratio where the results are slightly in favor of
the standard method. This is due to the different choice of the cutoff. In general, the proposal seems to perform better
than method NKK, except when the log odds ratio is reasonably large (FUT.1 and FUT.3). The latter is due to the fact that
method NKK ignores the uncertainty on the predicted values in cohort 2 when X happens to equal Y for all subjects in
cohort 1. Acknowledging this uncertainty is important however. Consider, for example, an interim analysis where data
for all patients are available; 50 in cohort 1 and 500 in cohort 2. Suppose that the data in cohort 1 show that X = Y: 22
patients with X = Y = 1 and 3 patients with X = Y = 0 in the experimental arm, and 18 patients with X = Y = 1 and 7
with X = Y = 0 in the control arm. Suppose further that 160 of the 250 patients in the control arm of cohort 2 are early
responders. If cohort 2 includes 177 early responders in the experimental arm, then the conditional power calculated by
method NKK is 0, meaning that at the time of the interim analysis, the probability to reject the null hypothesis at the
end of the trial is 0; it equals 1 if cohort 2 includes 178 early responders in the experimental arm. In such settings, it is
impossible to obtain a conditional power different from 0 or 1 and it may jump between these two extreme values when
an early nonresponder changes in an early responder or vice versa.
Similar simulations for tY = 0.20 and tX = 0.40 show that the advantage of using the expected conditional power
decreases with increasing cohort 1 sample size for a fixed interim sample size (see Supplementary Material). The differ-
ence in the amount of information between the proposed and standard method decreases since the amount of data in
cohort 2 decreases. Compared withmethod NKK, this is due to the fact that the prior information becomes less important
when cohort 1 sample size increases.
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FIGURE 3 Probability to stop for futility under FUT.2 and SUP.2 for different strengths of the association between X and Y in function of
cutoff points using the expected conditional power
3.3 Operational characteristics
3.3.1 Strength of the association
To further investigate the behavior of the estimators, different strengths of association between X and Y were considered
at tX = 0.40 and tY = 0.10: independent predictor (logOR1 = 0 and logOR0 = 0), weak correlation (logOR1 = 0.8
and logOR0 = 0.5), weak/low correlation (logOR1 = 1.3 and logOR0 = 0.8) denoted by low3, weak/low correlation
(logOR1 = 2 and logOR0 = 1.5) denoted by low2, weak/low correlation (logOR1 = 3 and logOR0 = 2) denoted by low1,
assumed correlation (logOR1 = 4.1 and logOR0 = 2.3), strong correlation (logOR1 = 7.4 and logOR0 = 4.1), and perfect
predictor (logOR1 = 100 and logOR0 = 100). Identical probabilities of success for Y and Xwere chosen in both treatment
arms: PY 1 = PX 1 = 0.73 and PY 0 = PX 0 = 0.60 for the superiority scenarios and PY 1 = PX 1 = PY 0 = PX 0 = 0.60 for the
true futility scenarios (ie, SUP.2 and FUT.2).
Figure 3 shows that the stronger the predictor, the higher the probability to stop under a true futility scenario. For the
superiority scenarios, we would expect the graphs to be in the reverse order, but this does not seem to be the case. This
is due to the fact that we rely more on the design assumptions as the log odds ratios become smaller (see Figure 2). If X
and Y are independent, we completely rely on the design assumptions. The curve is therefore similar, but higher due to
the extra variability induced by the posterior distribution, to the curve that we would get if we calculated the standard
conditional power. Since, in practice, the association between X and Y is unknown, it is recommended to assume a range
of association structures between both endpoints (eg, a perfect predictor, an X that is independent of Y, the log odds ratio
as observed in historical data, and the observed log odds ratio plus orminus 1.96 times its standard error) to protect against
a large loss of power when determining the cutoff value.
3.3.2 Varying information fractions
To investigate the influence of tX on the cutoff value for the conditional power, we evaluate the probability to stop for true
futility under scenario FUT.2 (assumed log odds ratio) using the cutoff values that result in a power loss of at most 1%
under scenario SUP.2 (assumed log odds ratio) for tY fixed at 0.10 and varying values for tX. The following information
fractions for X were considered: tX = (0.20, 0.30, 0.40, 0.50, 0.60). The probability to stop for futility under FUT.2 is 20%
when tX = 0.20 (cutoff: 0.66), 28% when tX = 0.30 (cutoff: 0.59), 34% when tX = 0.40 (cutoff: 0.51), 38% when tX = 0.50
(cutoff: 0.43), and 40%when tX = 0.60 (cutoff: 0.35). These probabilities to stop for futility using the expected conditional
power are shown in Figure 4. We see that the higher the information fraction for X, the lower the cutoff point can be
chosen and the higher the probability to stop under a true futility scenario.
To investigate the influence of tY on the cutoff value, we evaluate the probability to stop for true futility under scenario
FUT.2 (assumed log odds ratio) using the cutoff values that result in a power loss of at most 1% under scenario SUP.2
(assumed log odds ratio) for tX fixed at 0.40 and varying values for tY. We consider the following information fractions for
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FIGURE 4 Probability to stop for futility for varying choices of tX
and fixed tY = 0.10 under scenario FUT.2 (assumed log odds ratio)
for the cutoff value that results in a power loss of at most 1% under
scenario SUP.2
FIGURE 5 Probability to stop for futility for varying choices of tY
and fixed tX = 0.40 under scenario FUT.2 (assumed log odds ratio)
for the cutoff value that results in a power loss of at most 1% under
scenario SUP.2
Y: tY = (0.05, 0.10, 0.15, 0.20). As shown in Figure 5, the probability to stop for futility under FUT.2 is 35%when tY = 0.05
(cutoff: 0.50), 34% when tY = 0.10 (cutoff: 0.51), 38% when tY = 0.15 (cutoff: 0.53), and 41% when tY = 0.20 (cutoff: 0.53).
Thus, the higher the information fraction for Y, the higher the cutoff point that results in 1% power reduction and the
higher the probability to stop under a true futility scenario. Otherwise, the availability of primary endpoint dataY (cohort 1
data) improves the performance of the futility assessment; especially under scenarios where the observed outcome (in
terms of treatment difference) on the X data is different from the true treatment effect on Y, or lack thereof (see FUT.5 in
Supplementary Material).
4 DISCUSSION
In trials where accrual occurs fast compared to the planned length of follow-up, few subjects will have primary endpoint
data until close to the end of the study. This makes it difficult to accurately estimate the long-term response probability
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early in the study. We therefore proposed a method to incorporate short-term endpoint data (eg, an assessment of the
primary endpoint at an earlier time) and prior information for decision-making in the interim analysis. Our proposal
assumes that the prior information about the association between both endpoints and the observed association in cohort
1 is representative for cohort 2. This requires that the dependence between both endpoints does not change over time.
It should be assessed a priori whether this assumption is biologically plausible based on consultation with clinicians.
In addition,we recommend comparing the baseline covariates of patients in cohorts 1 and 2 to assesswhether the observed
data in cohort 1 may be representative of the future data. In future work, we will propose methods that can weaken these
assumptions by correcting for baseline covariates.
We generally found our proposal to perform better than the standard conditional power method and the conditional
power method introduced by Niewczas et al.11 The larger amount of information, obtained by incorporating short-term
endpoint data as well as historical data, resulted in a higher overall probability to stop for true futility.
The (minimal) values for tX and tY used in the example are specific to the context. In practice, one should do a simu-
lation study to determine the minimal number of patients needed in cohorts 1 and 2 (or equivalently, the proportion of
patients with long-term and short-term endpoint information) to obtain a reasonable probability to stop for true futility
and a negligible probability to incorrectly stop under the superiority scenarios. For the minimal tX, we propose using the
minimal proportion of primary endpoint data needed for the standard conditional power to obtain a reasonable proba-
bility to stop for true futility and a negligible probability to incorrectly stop under superiority as explained in the work
of Freidlin et al27 (eg, 37% for a one-sided 0.025 level design with a power of 90%). Subsequently, consider the minimal
number/proportion of these patients needed in cohort 1 to obtain a negligible probability to stop under the superiority
scenarios and a reasonable probability to correctly stop under the true futility scenarios.
In the motivating study, any missing observation was dealt with as an unfavorable outcome. For subjects in cohorts
2 and 3 who already discontinued from the trial, it is then known that they will not meet the criteria of a favorable
primary endpoint, even when they are not yet followed for the whole interval 𝜏Y. We recommend, however, that this
information is excluded from the analysis to avoid that the analysis is dominated by dropouts. Thus, for the subjects in
cohort 2, only available data up to 𝜏X are included in the analysis, while for the subjects in cohort 3, no data are included.
Although the proposed methodology has therefore been developed in the context of complete data, it still remains
valid when data are missing completely at random. When data are missing at random, standard missing data methods
(eg, multiple imputation) can be used to impute the missing data.
Conditional power computations are commonly evaluated at fixed values of the parameters PY1 and PY0 . It is more
cautious, however, to average the conditional power function with respect to the current knowledge or opinion about
PY1 and PY0 . The current knowledge about the underlying value of these parameters can be summarized using prior Beta
distributions. The predictive power28 can then be derived by averaging/integrating the conditional power over different
values 𝜋1 and 𝜋0 for, respectively, PY1 and PY0 , each one weighted according to the current belief about its probability by
means of a (posterior) distribution. In contrast to the conditional power approach, it produces an unconditional, predictive
probability of rejecting the null hypothesis and it avoids having to assume specific values for PY1 and PY0 . It therefore also
delivers a more robust power assessment.
This paper has focused on binary endpoints. An important generalization would be to enable continuous endpoints,
whether censored or not. Our proposal is limited to trial designs where only one specific short-term response is identi-
fied. In principle, when repeated measures at multiple intermediate time points are evaluated, including these repeated
measures could provide further efficiency gains. In future work, we will therefore develop a more generic proposal to
enable an interim evaluation of the treatment effect based on a combination of biomarkers, patient characteristics, and/or
intermediate endpoints.
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